The alpha1A-adrenergic receptor (a1A-AR) regulates various vascular functions and participates in the pathogenesis of primary hypertension. However, highly specific and subtype-selective antagonists of a1A-AR have not been developed.
Introduction
Alpha1-adrenergic receptors (a1-ARs), which belong to the superfamily of G protein-coupled receptors (GPCRs), exert multiple physiological and pathological functions. 1 They are heterogeneous and subdivided into three subtypes: a1A, a1B, and a1D. This classification is based on their encoded cDNAs and pharmacological and functional characteristics. 2 a1-ARs share a common structure that comprises seven transmembrane a-helices that are linked by three intracellular and extracellular loops. 3 The extracellular loops of a1-ARs are important regions of receptor functions, as demonstrated by several pieces of evidence. Gln-177, which is in the second extracellular loop, interacts with Asp-106, which is in the third transmembrane region in the starting structure. Norepinephrine binds to the receptor and disrupts this interaction, which is regarded as the first step of receptor activation. 4 Part of the second and third extracellular loops of the b-adrenergic receptor, which is highly similar to a1-ARs, participates in the formation of the 'roof' structure, which forms the ligand-receptor-binding pocket. a1A-AR is the predominant subtype that is expressed in resistance arteries in mice, rats, and humans and is an important therapeutic target for primary hypertension. 6, 7 The interaction between catecholamine (CA) and a1A-AR induces the prototypical signalling pathway of a1-ARs activation by increasing the intracellular Ca 2+ concentration, † These three authors contributed equally to this work.
activating protein kinase C (PKC) and extracellular signal-regulated kinases (ERK1/2), and finally regulating gene expression, arterial blood pressure elevation, cardiac hypertrophy and remodelling. 3, 8 However, drugs that induce a long-term and specific inhibition of the receptor have not been developed until recently. 9 Fortunately, antibodies which have a long half-life, high specificity and affinity provide a novel method to address this dilemma. Several researchers have discovered that antibodies specific for the GPCR play distinct roles as agonists or antagonists. 10 -12 In this study, we selected epitopes of a1A-AR and generated specific antibodies. The effects of the antibodies against a1A-AR were investigated on different levels in vitro. In vivo, we evaluated the function of the antibodies on systolic blood pressure (SBP) and mean blood pressure (MBP) in spontaneously hypertensive rats (SHRs). Our study identified a novel method for the investigation of GPCRs that have no specific inhibitors. This research also provided a new strategy for the treatment of primary hypertension.
Methods
Detailed methods are supplied in Supplementary material online.
Peptide synthesis
Two peptides corresponding to sequences of the extracellular loops of the rat a1A-AR were synthesized by GL Biochem Ltd (Shanghai, China) and termed CP-7 and CPE-8.
Antibody preparation
All procedures relevant to the care and use of animals in the current study conformed to the Guide for the Care and Use of Laboratory Animals published by the United States National Institutes of Health and were approved by the animal care committee of the University of Huazhong University of Science and Technology. New Zealand white rabbits were immunized with CP-7 or CPE-8 peptide that was conjugated to keyhole limpet haemocyanin (KLH). After eight subcutaneous injections, the antibody titres were determined using an enzyme-linked immunosorbent assay (ELISA). The serum was purified using protein A affinity chromatography (Bio-Rad). The antibodies against CP-7 and CPE-8 were termed anti-CP-7 and anti-CPE-8, respectively. Both antibodies were additionally purified by epitope-linked gel affinity chromatography (GE Healthcare), and the concentrations were confirmed by BCA kit (Pierce). The 'control antibody' was purified from rabbits that were immunized with KLH only. The peptide neutralization antibodies were produced by the co-incubation of 1 mg of each peptide and 1 mg of the respective antibody in phosphate-buffered solution for 8 h at 48C. The peptide neutralization antibodies were termed the NCP-7 (neutralization anti-CP-7) antibody and the NCPE-8 (neutralization anti-CPE-8) antibody.
Cell culture
Small arterial smooth muscle cells (SASMCs) were obtained from the superior mesenteric arteries of Sprague-Dawley rats ( 250 g), using the two-step method of enzymatic digestion as previously described. 13 Briefly, superior mesenteric arteries were isolated from male SpragueDawley rats and dissociated from the adventitial connective tissue. After two steps of digestion, SASMCs were cultivated in Dulbecco's modified Eagle's medium (DMEM) that was supplemented with 10% fetal bovine serum (FBS, HyClone). Primary neonatal cardiomyocytes were obtained from 2-3-day-old Sprague -Dawley rats, which were killed by cervical dislocation as previously described. 14 The hearts were obtained and minced into several pieces in PBS. The tissues were digested in an enzyme mixture containing 0.05% trypsin (Sigma) and 0.025% collagenase type II (Roche Applied Science) at 378C. Cells were collected by centrifugation at 1000 r.p.m. for 15 min and cultured in DMEM with 10% FBS. Human embryonic kidney 293 cells (HEK293, ATCC) were stably transfected with a pCDNA3.1 (+) vector expressing a1A-AR, which was constructed by our laboratory and cultured in DMEM containing 20% FBS.
Antibody identification
Western blotting and immunofluorescence were used to demonstrate that the anti-CP-7 and anti-CEP-8 antibodies specifically bound to a1A-AR. The protocols were similar to those previously described. 15 SASMCs, cardiomyocytes, or HEK293 cells that stably expressed a1A-AR were harvested. The total proteins were extracted using protein extraction buffer (Pierce) that contained a protease inhibitor cocktail (Roche Applied Science). Anti-CP-7 or anti-CEP-8 antibodies were used as primary antibodies.
Immunocytochemistry
SASMCs and cardiomyocytes were used in the current study and divided into groups as follows: the control group (no treatment) and six groups that were pre-incubated with the control antibody, 100 mmol/L prazosin (PRA, Sigma), the anti-CP-7 antibody, the NCP-7 antibody, the anti-CPE-8 antibody, and the NCPE-8 antibody. After pre-incubation for 40 min using the respective antibody (or PRA) for the six groups at 378C, 100 mmol/L phenylephrine (PHE, Sigma) was added to stimulate cells for 2 min. The PKC-a translocation was observed by laser confocal microscopy as previously described. 16 
Phosphorylated ERK1/2 levels
The design of the groups was identical to that for the PKC translocation experiment. SASMCs, neonatal rat cardiomyocytes, and HEK293 cells stably expressed a1A-AR were collected. The total proteins were extracted by centrifugation at 12 000 r.p.m. for 15 min at 48C. The level of ERK phosphorylation was detected using the phosphorylated-ERK1/2 (P-ERK1/2) monoclonal antibody (1:1000, Cell Signaling Technology). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control and was detected using the monoclonal anti-GAPDH antibody (1:1000, Cell Signaling Technology).
Intracellular Ca 21 concentration measurements
HEK293 cells that stably expressed a1A-AR were plated onto chamber slides (Nalge Nunc International) before measuring the cytosolic Ca 2+ concentration. The cells were divided into six groups: the control, anti-CP-7, anti-CPE-8, NCP-7, NCPE-8 antibody, and the PRA group. The cells in five groups were pre-incubated with the control, anti-CP-7, anti-CPE-8, NCP-7, or NCPE-8 antibody, respectively, for 40 min at 378C. Then the cells were incubated in DMEM with 20% FBS, Fluo-3-AM (final concentration of 5 mmol/L, Sigma-Aldrich), and Pluronic F127 (final concentration of 0.02%, Sigma-Aldrich). The measurement of the cytosolic Ca 2+ concentration was performed using an Olympus FV500 confocal system (Japan). A total of 10 mL PHE (final concentration at 100 mmol/L) was added to the chamber, and the fluorescence intensity was recorded. The cells in the PRA group were pre-incubated with PRA (100 mmol/L) for 10 min after loaded with Fluo-3-AM, and then stimulated with 100 mmol/L PHE.
Beating rate assay
Cardiomyocytes from neonatal rats were prepared as described above. At the beginning of the current study, at least three clusters of cardiomyocytes per well were chosen, and the basal beating rates were recorded for 1 min at 378C. The cells were grouped and incubated with the control antibody, the anti-CP-7 antibody, the anti-CPE-8 antibody, or PRA (100 mmol/L) for 1 h. The beating rates of the cardiomyocytes were counted for each group. Then PHE (100 mmol/L) was added and the beating rates were counted again. The microscope stage was heated to maintain a steady temperature during the counting process. The experiments were repeated at least three times.
Radioligand binding
Radioligand binding studies in membrane protein were performed as described previously. 17 -20 
Blood pressure measurements
The blood pressure of SHRs was measured using the tail-cuff method (BP-98a, Japan) before immunization. Twelve-week-old SHRs (n ¼ 10) were immunized with 100 mg of peptide -KLH complex in aluminium hydroxide per rat. The control group (n ¼ 10) was immunized with 100 mg of KLH per rat. The animals were boosted on days 14, 28, 35, 42, 49, 56, 63, and 77. The antibody titres were screened on days 0, 21, 28, 35, 42, 49, 56, 63, and 84. The SBP, MBP, and heart rate were calculated from 20 readings for each rat.
Statistics
The data were expressed as the means + SE. The ANOVA test was used to compare variables among groups. The one-way repeated measures ANOVA was used for the SBP, MBP, and heart rate data analysis. The Pearson correlation analysis and a multiple linear regression analysis were used to analyse the relationship between SBP, MBP variation, and the anti-CP-7 antibody titre. P , 0.05 was accepted as significant.
Results

Antibodies specifically bound to a1A-AR in SASMCs, cardiomyocytes, and HEK293 cells
To demonstrate that the antibodies specifically bound to a1A-AR, the anti-CP-7 and anti-CPE-8 antibodies were used as the primary antibody for western blot analysis and immunofluorescence. Only the band representing a1A-AR ( 52 kDa) was detected by the anti-CP-7 or anti-CPE-8 antibodies; this band was not detected by the control antibody ( Figure 1A) . Immunofluorescent staining showed that the anti-CP-7 and anti-CPE-8 antibodies specifically bound to membrane a1A-AR ( Figure 1B) . Neither the anti-CP-7 nor anti-CPE-8 antibodies could detect the proteins that were extracted from HEK293 cells that were transfected with a1B-AR or a1D-AR using western blot analysis and immunofluorescence (data showed in Supplementary material online).
Anti-CP-7 antibody inhibited PHE-induced PKC-a translocation in cardiomyocytes and SASMCs
PKC-a translocation, which is considered the hallmark of GPCR activation, was investigated in our current study. In the control group, the PKC-a was broadly distributed in a diffuse pattern in unstimulated cardiomyocytes or SASMC. PHE dramatically promoted PKC-a translocation to an area surrounding the nucleus. In Figure 2A , preincubation with PRA inhibited the effect of PHE. Similarly, a 40 min pre-incubation of the cardiomyocytes with the anti-CP-7 antibody dramatically inhibited PHE-induced PKC translocation compared with cardiomyocytes that were pre-incubated with the control antibody and the NCP-7 antibody. There were no significant differences in the translocation of PKC-a among groups that were pre-incubated with the control antibody, the anti-CPE-8 antibody, and the NCPE-8 antibody. The results were identical in both cardiomyocytes ( Figure 2A) and SASMCs ( Figure 2B ).
Anti-CP-7 antibody inhibited PHE-induced ERK phosphorylation
The phosphorylation level of ERK, which is another sign of a1A-AR activation, was evaluated using western blot analysis. After PHE stimulation, phosphorylated ERK1/2 displayed a 4.54-fold increase in expression in the control antibody-pre-incubated group compared with the control group (no treatment) in cardiomyocytes. The PHE-induced expression of phosphorylated ERK1/2 was inhibited by PRA ( 38% compared with the control antibody-pre-incubated group). The anti-CP-7 antibody-pre-incubation inhibited ERK1/2 phosphorylation by 28% compared with the NCP-7 antibody-pre-incubation (P ¼ 0.016) and by 27% compared with the control antibody-pre-incubation (P ¼ 0.023). Nevertheless, there was no significant difference in ERK1/2 phosphorylation between the anti-CPE-8 antibody-and the control antibody-pre-incubated groups (P ¼ 0.725) ( Figure 3A) . These findings were confirmed in HEK293 cells that stably expressed a1A-AR ( Figure 3C ). However, in cultured SASMCs from superior mesenteric arteries, the anti-CP-7 antibody had no inhibitory effect on ERK1/2 phosphorylation compared with the NCP-7 antibody (P ¼ 0.911) and the control antibody (P ¼ 0.588) ( Figure 3B ).
Anti-CP-7 antibody inhibited PHE-induced elevation of intracellular Ca 21 concentrations
We measured the intracellular Ca 2+ concentration using a confocal imaging system. In the control antibody-and NCP-7 antibody-pre-incubated groups, the fluorescence intensity rapidly increased, reached to a peak, and then slowly decreased back to the basal level after stimulation with 100 mmol/L PHE ( Figure 4A and D) . The relative fluorescence intensities (RFIs) were 8.86 + 0.50 and 9.93 + 1.18, respectively, in the control antibody-and NCP-7 antibody-pre-incubated groups. In the anti-CP-7 antibody-pre-incubated group ( Figure 4C ), the RFI was 5.55 + 0.26, which was significantly lower compared with the control antibody-(P ¼ 0.006) and NCP-7 antibody-pre-incubated group (P ¼ 0.000). However, it was significantly higher compared with the PRA-pre-incubated group (RFI ¼ 2.47 + 0.18) (P ¼ 0.011) ( Figure 4B ). No significant differences were observed among the anti-CPE-8 antibody-, the control antibody-, and the NCPE-8 antibody-pre-incubated groups ( Figure 4G ).
3.5 Anti-CP-7 antibody inhibited the beating rates of cardiomyocytes at basal and PHE-stimulated levels
In primary neonatal rat cardiomyocytes, CAs activate the a1A-AR and regulate the intracellular Ca 2+ concentration to maintain the basal heart beat. 21 In the current study, the basal beating rates of cardiomyocytes was 142 + 4 b.p.m. No significant difference was observed 
Neither antibody prevented [ 3 H]-epinephrine or [ 3 H]-prazosin from binding to the receptor
In our study, pre-incubation with the anti-CP-7 antibody inhibited the PHE-stimulated a1A-AR activation. As illustrated in Figure 5B , phentolamine competed for binding to the a1A-AR in a dose-dependent manner. Over 95% of [ 3 H]-prazosin was displaced by phentolamine at high test concentrations. The obtained IC50 was 8.2 nM and Ki was 3.8 nM, which indicated that this assay was valid for the sample testing. For both the anti-CP-7 and anti-CPE-8 antibodies, as illustrated in Figure 5B , no significant displacements of [ anti-CP-7 and anti-CPE-8 antibody generated and purified could specifically recognize and bind to a1A-AR protein ( 52 kDa) extracted from SASMCs, cardiomyocytes, and HEK293 cells, respectively. But the control antibody could not detect the a1A-AR protein. (B) Three types of different cells were cultured on glass cover slips and incubated with anti-CP-7 and anti-CPE-8 antibodies. NCP-7 signified anti-CP-7 antibody neutralized by peptide CP-7; NCPE-8 signified anti-CPE-8 antibody neutralized by peptide CPE-8. Control signified control antibody. The nuclei were stained with DAPI. Fluorescent images were processed using Olympus FV500 confocal microscopy (Japan). Bar equates to 20 mm. result was observed in the competition assay with [ 3 H]-epinephrine ( Figure 5C ).
In vivo CP-7-KLH immunization decreased the SBP of SHRs
In vivo, the mean SBP of SHRs that were immunized with CP-7-KLH was significantly lower compared with the KLH-immunized group on day 35, with a difference of 14 mmHg ( Figure 6C ). During the process of SBP testing, the antibody titre was monitored using ELISA. The anti-CP-7 antibody was detected on day 21, and the titre reached a peak (1:4800) on day 42 ( Figure 6A) . From day 63, there was no significant difference in the SBP between the CP-7-KLH group and the KLH group, and the antibody titre decreased quickly ( Figure 6A and C ) . The Pearson correlation analysis showed that SBP variation (SBP KLH 2 SBP CP-7-KLH ) was positively correlated with the titre of anti-CP-7, which was expressed as the OD 430nm value of diluted serum (1:300) obtained from rats immunized with CP-7-KLH ( Figure 6F ). The multiple linear regression analysis indicated that the SBP variation (SBP KLH 2 SBP CP-7-KLH ) was independently associated with the antibody titre ( Table 1) . There were no obvious differences in the SBPs of the CPE-8-KLH-immunized group and the KLH-immunized group during the immunization procedure although a higher antibody titre was generated by the CPE-8-KLH immunization ( Figure 6B and C) . The variation of MBP in the CP-7-KLH-immunized group was identical to SBP ( Figure 6G ; Table 2 ). There were no differences in the heart rates of CP-7-KLH-and CPE-8-KLH-immunized groups compared with the KLH-immunized group ( Figure 6E ).
Discussion
The key process of the current study was the production of an antibody that specifically inhibits the a1A-adrenergic receptor. Many researchers have tried to identify a GPCR antibody that acts as an agonist or an antagonist. 10, 22 The classical example is the autoantibodies that are detected in patients with Graves' disease and have displayed various functions, including activation, inhibition, or antigen-antibody binding without signal transduction activity. 10 Antibodies against b-ARs, a1-ARs, and angiotensin II type 1 receptors have also been successively identified and were shown to play important roles in the pathological process in primary cardiomyopathy, hypertension, and pre-eclampsia. 22, 23 In our previous research, we identified the second extracellular segment of a1D-AR as an effective epitope that induced the production of a specific antibody and caused cardiovascular damage. 24 Antibodies against a1-ARs have also been found in malignant hypertensive patients and were shown to induce vascular remodelling. 11 Similar results have been reported by several groups. 12 The existence of an agonist-like auto-antibody against a1-ARs in hypertensive patients has been shown. However, the researchers neglected the presence of a potentially inhibitory antibody against a1-ARs, especially a1A-AR, which is widely expressed in resistance arteries and participates in the regulation and the maintenance of blood pressure. 7 By analysing the structure of a1A-AR, we confirmed that the extracellular regions that contain crucial amino acid sequences play an important role in receptor activation. 4 We designed two peptides that were termed CP-7 and CPE-8 and obtained antibodies against these peptides from immunized rabbits. After purifying the antibodies using protein A affinity chromatography, Figure 3 The anti-CP-7 antibody inhibited PHE-induced ERK phosphorylation. The phosphorylation level of ERK of cardiomyocytes (A), SASMCs (B), and HEK293 cells (C) after stimulated by phenylephrine (PHE, 100 mmol/L). The three types of cells were pre-incubated with control antibody (Con-Anti), prazosin (PRA), anti-CP-7 antibody (anti-CP-7), anti-CP-7 antibody neutralized by peptide CP-7 (NCP-7), anti-CPE-8 antibody (anti-CPE-8), and anti-CPE-8 antibody neutralized by peptide CPE-8 (NCPE-8) separately. The whole-cell extracts were analysed using western blotting with phosphorylated-ERK1/2(P-ERK1/2) antibody and quantitated by densitometric analysis. Results were obtained from at least three independent experiments. # P , 0.05 compared with the control group, *P , 0.05 compared with the control antibody group, **P . 0.05 compared with the control antibody group. Figure 4 The anti-CP-7 antibody inhibited PHE-induced elevation of intracellular Ca 2+ concentrations. HEK293 cells stably expressing a1A-AR were pre-incubated with control antibody (Con-Anti), prazosin (PRA), anti-CP-7 antibody (anti-CP-7), anti-CP-7 antibody neutralized by peptide CP-7 (NCP-7), anti-CPE-8 antibody (anti-CPE-8), and anti-CPE-8 antibody neutralized by peptide CPE-8 (NCPE-8), respectively. PHE (100 mmol/L) was added to each group, and intracellular Ca 2+ concentration calculated by the fluorescence intensity was measured through confocal imaging system. F 0 , the basic fluorescence intensity; F max , the maximum fluorescence intensity; (F max -F 0 )/F 0 , relative fluorescence intensity. Results were obtained from at least three independent experiments. *P , 0.05 compared with the control antibody group, **P . 0.05 compared with the control antibody group. # P , 0.05 compared with the Anti-CP-7 antibody group.
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epitope-linked gel affinity chromatography was performed to guarantee the high specificity of the antibody. These antibodies were shown to specifically bind to a1A-AR by immunofluorescence and western blotting. PKC translocation and ERK phosphorylation are classical processes related to a1A-AR activation. 3 SASMCs and neonatal rat cardiomyocytes, which mainly express a1A-adrenergic receptors, were chosen for the current study. In addition, to further elucidate the function of the antibody against the a1A-adrenergic receptor, we constructed an HEK293 cell line that stably expressed a1A-AR. In the PKC translocation experiments, SASMCs and neonatal rat cardiomyocytes showed that the anti-CP-7 antibody treatment effectively inhibited PHE-induced PKC translocation compared with both the control antibody and the CP-7 peptide neutralization antibody treatment. However, the A research for a novel a1A-adrenoceptor antibody Figure 6 In vivo CP-7-KLH immunization decreased the blood pressure of SHRs. Antibody titre expressed as the OD 430nm value of serum which was diluted at 1:300 (A and B), blood pressure (C and D), and heart rates (E) of SHR during the immunization process are showed. anti-CPE-8 antibody had no inhibitory effect. Interestingly, ERK phosphorylation inhibition was only observed in neonatal rat cardiomyocytes and HEK293 cells. In SASMCs, the anti-CP-7 antibody had no inhibitory effect on ERK phosphorylation compared with the control antibody and the CP-7 peptide neutralization antibody. One possible explanation is the following: in the PKC translocation experiment, SASMCs were prepared by acute separation, which is different from the preparation in the ERK phosphorylation test. In this experiment, we found that a1A-AR was no longer highly expressed in cultured SASMCs compared with that in native tissue and acutely separated SASMCs. Conversely, in cultured SASMCs, the a1D-AR became the major receptor that was detected at the mRNA level (showed in Supplementary material online). PHE is an agonist of a1-ARs, so it activated both a1A-AR and a1D-AR. Our results are supported by other studies. 25 The alteration in the expression and distribution of a1-ARs antibody. However, the results in vitro demonstrated that the anti-CP-7 antibody effectively inhibited the a1A-AR activation induced by PHE. We had confirmed that anti-CP-7 antibody did not activate or inhibit the a1A-AR directly (showed in Supplementary material online). One possible mechanism was the antibody bound to the receptor and caused a conformational change, which prevented the biological function of PHE. It meant that a1A-AR was no longer sensitive to PHE treatment once the antibody was bound to the receptor. The inhibitory effect of the anti-CP-7 antibody was not diminished with increasing concentration of PHE.
We tested the effect of the anti-CP-7 antibody on blood pressure in animals by conjugating the CP-7 peptide with KLH and then immunizing SHRs. The results reveal that SBP and MBP in the CP-7-KLH-immunized group were lower than those in the control group on day 32. However, after day 63, the blood pressure readings of the two groups were not significantly different, which we attributed to the decline in the antibody titre. Two factors may be involved: (i) CP-7 is an innate epitope in rats and (ii) SHRs display characteristics of immunosuppression and low immunoreactivity, as shown by studies that the number of T cells of SHR dramatically decreases with time and eventually causes the suppression of immunoreactivity. 26 The number of T cells in SHRs decreased at 8 weeks of age. At the same time point, SHRs exhibited dramatic increases in blood pressure. These factors led to a therapeutic window that was short compared with our expectation. However, the preliminary experiment in vivo supplied us with the evidence that the antigen-targeting peptide CP-7 could decrease the blood pressure.
In our research, all the data demonstrate that the antibody against the epitope CP-7 inhibited the activation of a1A-AR induced by PHE. However, the inhibitive effect of the anti-CP-7 antibody was not as dramatic as that of PRA in vitro. The results require further investigation and must be cautiously interpreted. The most important contribution of our study is a candidate epitope for immunological therapy for hypertension. When a peptide is conjugated with a carrier protein such as bovine serum albumin, KLH, or virus-like particles (VLPs), the conjugate becomes a vaccine. Compared with traditional chemical drugs for the treatment of hypertension that target a1A-AR, such as PRA or terazosin, the vaccine used in the current study possessed many benefits, including high selectivity and long-term activity. More importantly, when the vaccine was used, the generation of antibodies and its inhibitory effects occurred gradually. Therefore, the low blood pressure that was induced by the initial treatment with the aforementioned drugs was avoided and the decrease in blood pressure was more steady and smooth. The antibody that was purified from immunized animals was polyclonal and consisted of antibodies with different affinity. The dose-response relationship could not be evaluated exactly in our experiment. Therefore, it was difficult to compare the effects of PRA and the anti-CP-7 antibody. The use of a monoclonal antibody may solve this problem.
The use of novel carrier proteins such as VLPs and the application of new adjuvants could significantly elevate the antibody titre. However, our results are based on a preliminary experiment. We showed that the vaccine target peptide, CP-7, decreased blood pressure, providing a novel strategy for the treatment of primary hypertension. In addition, our study provided a new pathway for the investigation of GPCRs that lack a specific antagonist.
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